What is OVID's P/E ratio?

Ovid Therapeutics Inc (OVID) currently trades at a P/E ratio of 45.00.

Ovid Therapeutics Inc reports a Return on Equity (ROE) of -12.19%.

What is OVID's dividend yield?

Ovid Therapeutics Inc offers a dividend yield of 0.00%.

What is OVID's Quality Score?

Our AI rates OVID's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy OVID?

Our AI Timing Score for OVID is 28 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does OVID belong to?

Ovid Therapeutics Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Ovid Therapeutics Inc (OVID) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

OVID AI Analysis Summary

Our AI summary for OVID: Ovid Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 45.00, ROE of -12.19%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 28/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

OVID

Ovid Therapeutics Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 93

USD 2.54

0.21 (9.01%) Day Change

Watchlist Portfolio Compare Chart

45.00

P/E

0.01

D/E

-12.2%

ROE

-10.7%

ROA

0.00%

Div Yield

-1.59

PEG

OVID THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 2.54 Price 0.21 (9.01%) Day Change	NEWS SCORE: 93

OVID, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	93
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	2.54
PBV / Sector	2.19 / 44,022.72
Earning Per Share	-0.14

PE / Sector	45.00 / 19.17
PEG or PE/Growth / Sector	-1.59 / 1.24
Average 1M Daily Value	3.83 M GREAT
Average 1W Daily Value	3.28 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-339.33 / 98.24
NPM Average (%) / Sector	-4,404.47 / -1,697.63
NPM Change Average (%) / Sector	42.93 / 5,097.97 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-10.71 / 185,260.96
ROA Average (%) / Sector	-24.08 / 36,684.70
ROA Change Average (%) / Sector	-19.56 / 422,221.66
ROE (%) / Sector	-12.19 / 243,762.23
ROE Average (%) / Sector	-32.55 / 48,758.47
ROE Change Average (%) / Sector	-13.94 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:39
Symbol	OVID
Name	OVID THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	186.64 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	434.87 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Hudson Commons, New York, NY, United States, 10001

Phone: 646 661 7661

Website: https://www.ovidrx.com

Sector: Healthcare >> Biotechnology

Description: Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.